Agilent/Dako

CD 274, Programmed cell death 1 ligand 1 (B7-H1)

#M3653 · immunohistochemistry

56

Citing papers

905

Combined citations

Supplier page Find this product

Research areas

Cancer Immunotherapy and Biomarkers33 Immunotherapy and Immune Responses8 Cancer Genomics and Diagnostics7 Ovarian cancer diagnosis and treatment5 Cancer, Stress, Anesthesia, and Immune Response4 Cancer Cells and Metastasis4 Lung Cancer Treatments and Mutations4 Pancreatic and Hepatic Oncology Research4

Papers citing this product

1

Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

International Journal of Molecular Sciences·2019·200 cit.·DOI

2

First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients

Journal of Nuclear Medicine·2021·129 cit.·DOI

3

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Nature Communications·2022·82 cit.·DOI

4

<scp><i>NTRK</i></scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability

Cancer Medicine·2022·65 cit.·DOI

5

PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients

Oncotarget·2017·51 cit.·DOI

6

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Frontiers in Oncology·2021·38 cit.·DOI

7

Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)

European Journal of Cancer·2023·35 cit.·DOI

8

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)

Cell Reports Medicine·2024·31 cit.·DOI

9

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients

Archives of Gynecology and Obstetrics·2022·23 cit.·DOI

10

Endoscopic calcium electroporation for colorectal cancer: a phase I study

Endoscopy International Open·2023·21 cit.·DOI

Also available from other vendors

This target has 114 citing papers across all vendors combined

Vendor	Product	Evidence	Price	Papers
Agilent/Dako	PD-L1 IHC 22C3 pharmDx for Autostainer Link 48	—	—	59

Similar products

Product	Vendor	Evidence	Price	Papers
CD 274, Programmed cell death 1 ligand 1 (B7-H1)	Spring Bioscience	—	—	13

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.